PROFILE 1014: lessons for the new era of lung cancer clinical research

In 2014, Solomon et al. published the PROFILE 1014 phase III trial comparing crizotinib to first line platinum-pemetrexed chemotherapy in treatment na？ve advanced anaplastic lymphoma kinase positive (ALK+) rearranged non-small cell lung cancer (NSCLC) (1). By looking carefully at the design and outcomes from this study, we can learn several important lessons about the way in which lung cancer clinical research is evolving, or will have to evolve, to remain meaningful in the new era of personalized molecular therapies